Halozyme Therapeutics, Inc. (HALO)

NASDAQ: HALO · Real-Time Price · USD

100.27

-0.40 (-0.40%)

At close: Nov 13, 2026, 4:00 PM EST

99.48

-0.79 (-0.79%)

After-hours: Nov 13, 2026, 7:56 PM EST

Halozyme Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 13, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	11,432	7,914	6,083	4,882	7,694	5,659
Market Cap Growth	38.62%	30.11%	24.59%	-36.54%	35.96%	-1.84%
Enterprise Value	13,637	8,751	6,951	5,929	8,940	5,722
Last Close Price	100.27	67.30	47.81	36.96	56.90	40.21

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 13, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	25.26	24.98	13.70	17.34	38.06	14.05
Forward PE	9.55	8.85	10.38	9.77	21.92	17.89
PS Ratio	6.34	5.67	5.99	5.89	11.66	12.76
PB Ratio	-	162.13	16.72	58.26	45.31	28.73
P/TBV Ratio	-	-	-	-	-	28.73
P/FCF Ratio	12.90	12.28	12.99	13.08	32.70	18.99
P/OCF Ratio	12.73	12.15	12.70	12.57	32.04	18.90
PEG Ratio	-	0.55	0.55	0.90	0.91	0.46

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 13, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EV/Sales Ratio	7.57	6.27	6.85	7.15	13.54	12.91
EV/EBITDA Ratio	11.96	9.75	11.09	14.22	26.60	20.63
EV/EBIT Ratio	13.35	10.72	12.61	17.56	30.89	20.74
EV/FCF Ratio	15.39	13.58	14.84	15.88	37.99	19.20

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 13, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Debt / Equity Ratio	-59.36	44.60	4.14	18.27	9.07	4.47
Debt / EBITDA Ratio	2.84	2.40	2.38	3.59	4.54	3.15
Debt / FCF Ratio	3.70	3.38	3.22	4.10	6.55	2.95
Net Debt / Equity Ratio	-39.91	41.68	2.50	14.26	6.94	0.70
Net Debt / EBITDA Ratio	1.93	2.27	1.45	2.87	3.51	0.50
Net Debt / FCF Ratio	2.49	3.16	1.94	3.20	5.01	0.47
Asset Turnover	0.63	0.61	0.54	0.46	0.45	0.53
Inventory Turnover	2.72	1.95	1.77	2.36	2.67	2.04
Quick Ratio	3.36	3.30	6.50	5.07	4.54	7.10
Current Ratio	3.88	4.66	7.80	6.64	5.65	7.91
Return on Equity (ROE)	216.38%	153.59%	198.42%	222.07%	110.23%	231.44%
Return on Assets (ROA)	22.42%	22.24%	18.16%	11.80%	12.28%	20.47%
Return on Invested Capital (ROIC)	29.76%	33.01%	34.44%	20.77%	27.92%	105.98%
Return on Capital Employed (ROCE)	34.10%	34.80%	28.70%	20.80%	16.90%	27.90%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Nov '26 Nov 13, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Earnings Yield	3.96%	4.00%	7.30%	5.77%	2.63%	7.12%
FCF Yield	7.75%	8.14%	7.70%	7.65%	3.06%	5.27%
Buyback Yield / Dilution	2.62%	4.26%	3.56%	4.56%	4.21%	-3.77%

SEC Filings: 10-K · 10-Q